Track Certara, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Certara, Inc. CERT · Stock Open Certara, Inc. in new tab

11.57 USD
P/E
101.14
EPS
-0.18
P/B
1.80
ROE
-2.08
Beta
1.25
Target Price
12.68 USD
Certara, Inc. logo

Certara, Inc.

🧾 Earnings Recap – Q3 2026

Certara’s shares rose 9.8% after earnings, as software growth reaccelerated to double digits and bookings increased 15%. The positive signal was tempered by services revenue declining 2% year over year and management’s view that the impact of its corrective actions will take time to show.

  • Q3 revenue was $94.9 million, up 4% year over year on a continuing-operations basis; adjusted EBITDA rose 6% to $30.2 million, with a 31.8% margin.
  • Software revenue grew 11% to $48.8 million, its first double-digit organic growth quarter in two years. Software bookings increased 15% to $46.9 million.
  • Services revenue fell 2% to $46.1 million, though it grew 3.5% sequentially. Services bookings were $45.6 million, and trailing 12-month book-to-bill was 1.15.
  • Management expects new AI capabilities to contribute further to growth and positioning in 2027; nearly 10% of Phoenix Cloud accounts have migrated to the cloud so far.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
P/E101.14
EPS-0.18
Book Value6.41
Price to Book1.80
Debt/Equity30.80
% Insiders3.585%
Growth
Revenue Growth0.04%
Earnings Growth2.85%
Estimates
Forward P/E29.57
Forward EPS0.39
Target Mean Price12.68

DCF valuation

Model fair value for Certara, Inc. (CERT)
Result
Sign in to run the valuation for CERT.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
11 analysts · consensus Buy · mean target 12.68 USD (low 10.00, high 15.00) · as of 15 Nov 2026
Low 10.00
Mean 12.68
High 15.00
Price 11.57
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Certara, Inc. Logo Certara, Inc. Analysis (CERT)

United States Health Care Official Website Stock

Is Certara, Inc. a good investment? Certara, Inc. (CERT) is currently trading at 11.57 USD. Market analysts have a consensus price target of 12.68 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 101.14. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Certara, Inc. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is 0.39.

Investor FAQ

Does Certara, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Certara, Inc.?

Certara, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of -0.18.

Company Profile

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Exchange Ticker
NMS (United States) CERT
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion